Treatment of adult T-cell leukemia/lymphoma: past, present, and future

被引：55
作者：
Ishitsuka, Kenji [1 ]
Tamura, Kazuo [1 ]
机构：
[1] Fukuoka Univ, Div Hematol & Oncol, Fukuoka 8140180, Japan
来源：
EUROPEAN JOURNAL OF HAEMATOLOGY | 2008年 / 80卷 / 03期
关键词：
adult T-cell leukemia/lymphoma; human T-cell lymphotrophic virus type I; treatment; novel therapy;
D O I：
10.1111/j.1600-0609.2007.01016.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell malignancy caused by human T-cell lymphotrophic virus type I. Clinical manifestations of ATLL range from smoldering to chronic, lymphoma and acute. Patients with acute and lymphoma type ATLL require therapeutic intervention. Conventional chemotherapeutic regimens used against other malignant lymphoma have been administered to ATLL patients, but the therapeutic outcomes of acute and lymphoma type ATLL remain very poor. Promising results of allogeneic stem cell transplantation (SCT) for ATLL patients have recently been reported and the treatment outcome might be improved for some ATLL patients. Besides conventional chemotherapy and SCT, interferon, zidovudine, arsenic trioxide, targeted therapy against surface molecule on ATLL cells, retinoid derivatives, and bortezomib have been administered to ATLL patients in pilot or phase I/II studies. Further studies are required to confirm the clinical benefits of these novel therapeutics. This article reviews the current status and future directions of ATLL treatment.
引用
收藏
页码：185 / 196
页数：12
相关论文
共 164 条
[1]   Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro [J].
Balestrieri, E ;
Forte, G ;
Matteucci, C ;
Mastino, A ;
Macchi, B .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (09) :3080-3083
[2]   HTLV-1 TAX INDUCES CELLULAR PROTEINS THAT ACTIVATE THE KAPPA-B ELEMENT IN THE IL-2 RECEPTOR ALPHA-GENE [J].
BALLARD, DW ;
BOHNLEIN, E ;
LOWENTHAL, JW ;
WANO, Y ;
FRANZA, BR ;
GREENE, WC .
SCIENCE, 1988, 241 (4873) :1652-1655
[3]   Cellular immune response to HTLV-1 [J].
Bangham, CRM ;
Osame, M .
ONCOGENE, 2005, 24 (39) :6035-6046
[4]   Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration [J].
Barmak, K ;
Harhaj, E ;
Grant, C ;
Alefantis, T ;
Wigdahl, B .
VIROLOGY, 2003, 308 (01) :1-12
[5]   New therapeutic approaches for adult T-cell leukaemia [J].
Bazarbachi, A ;
Ghez, D ;
Lepelletier, Y ;
Nasr, R ;
de Thé, H ;
El-Sabban, ME ;
Hermine, O .
LANCET ONCOLOGY, 2004, 5 (11) :664-672
[6]   Arsenic trioxide and interferon-α synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells [J].
Bazarbachi, A ;
El-Sabban, ME ;
Nasr, R ;
Quignon, F ;
Awaraji, C ;
Kersual, J ;
Dianoux, L ;
Zermati, Y ;
Haidar, JH ;
Hermine, O ;
de Thé, H .
BLOOD, 1999, 93 (01) :278-283
[7]   Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma [J].
Bazarbachi, A ;
Nasr, R ;
El-Sabban, ME ;
Mahé, A ;
Mahieux, R ;
Gessain, A ;
Darwiche, N ;
Dbaibo, G ;
Kersual, J ;
Zermati, Y ;
Dianoux, L ;
Chelbi-Alix, MK ;
de Thé, H ;
Hermine, O .
LEUKEMIA, 2000, 14 (04) :716-721
[8]   Emodin and DHA potently increase arsenic trioxide interferon-α-induced cell death of HILV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1 [J].
Brown, Megan ;
Bellon, Marcia ;
Nicot, Christophe .
BLOOD, 2007, 109 (04) :1653-1659
[9]   Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line [J].
Brown, T ;
Sigurdson, E ;
Rogatko, A ;
Broccoli, D .
ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (08) :910-915
[10]  
CALLENS C, 2007, LEUKEMIA 0927
12345678910